Continuing the tradition of providing you with timely market feedback from ASCO 2011, OBR and MDoutlook are pleased to share results from MDoutlook's 4th Annual post-ASCO survey fielded among its global network of 52,000 cancer physicians.
The first Quick-Poll published in the OBR blog will cover one of the hottest topics at ASCO - melanoma. Following these results and analysis we'll publish on the other tumor types listed below.
Quick Poll Methodology and Respondents’ Geographic Distribution
1) Melanoma Treaters Plan to Treat a Majority of Their V600E BRAF+ Melanoma Patients with Vemurafenib
2) Physicians Plan Selective Usage of Ipilimumab in Their Advanced and Metastatic Melanoma Patients with Ipilimumab
3) Melanoma Treaters Rate Clinical Importance of Clinical Trial of GSK212 (MEK inhibitor) and GSK436 (BRAF) as Highly Important
4) Majority of Melanoma Patients Will Be Screened for V600E BRAF Mutation in the Next Year
Quick polls are a fast way of measuring expected acceptance of clinical data post major medical meetings, and perhaps can be used to make some assumptions about adoption amongst providers. In today’s information hungry environment, the speed at which these polls can be conducted and analyzed can be advantageous for market planning and “pressure testing” acceptance of data amongst key stakeholders.
Submitted by Stefan Terwindt, EVP, The Arcas Group
You must be logged in to post a comment